TwentyTwo Real Estate and Farallon Capital Complete €761 Million Investment in Isemia, a €1.2bn Healthcare Real Estate Company Created With emeis
14.1.2026 18:30:00 CET | Business Wire | Press Release
TwentyTwo Real Estate, an independent European real estate investment and management firm, announces the completion, alongside Farallon Capital, of a €761 million investment that led to the creation of Isemia (www.isemiabyemeis.com), a leading healthcare real estate company holding a €1.2 billion portfolio of assets operated by emeis. The transaction represents a significant milestone in TwentyTwo Real Estate’s long-term investment strategy focused on healthcare and operational living real estate.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114262830/en/
Fachklinik Schömberg
Isemia comprises 68 high-quality assets across France, Germany and Spain, with a balanced mix of nursing homes (48%) and clinics (52%). The portfolio benefits from strong fundamentals and resilient operating performance. All properties will continue to be operated by emeis under long-term lease agreements, ensuring continuity of care for residents and patients while maintaining close alignment between real estate ownership and operations.
The investment has been structured through the subscription of financial securities, including preferred shares, designed to deliver stable and predictable returns, with a minimum 6% yield and an expected unlevered IRR of approximately 12%.
This transaction represents a further step in TwentyTwo Real Estate’s strategy of investing in operationally intensive assets within the living and healthcare sectors, where strong real estate fundamentals, combined with operational expertise, underpin long-term, sustainable value creation. It follows the recent launch of the firm’s senior living investment platform, Premior Residences, seeded with an initial portfolio of c.1,900 units, and reflects TwentyTwo Real Estate’s continued expansion in Western Europe, as well as its focus on thematic investments driven by major demographic and societal trends.
Daniel Rigny, Founder and Chairman of TwentyTwo Real Estate, commented:
“This investment represents a major step in our expansion into healthcare and operational living real estate. Isemia’s portfolio comprises high-quality assets, characterized by their resilience and strong social utility. In partnership with emeis and Farallon Capital, we are establishing a leading real estate company addressing Europe’s structural demographic and healthcare needs while delivering robust fundamentals and sustainable value creation for long-term investors. We are proud to have completed this strategic transaction, which reflects our investment convictions, our ability to design innovative financial solutions and our capacity to mobilize our operational expertise.”
About TwentyTwo Real Estate
TwentyTwo Real Estate is an independent real estate investor and operator with €5.2 billion in assets under management in Europe. Founded in 2012 by Daniel Rigny, the group combines cutting-edge financial expertise and operational excellence to offer its institutional and private clients a range of high value-added investment solutions and real estate services across all asset classes. TwentyTwo Real Estate's mission is to create sustainable value for its investors, clients, and employees, while having a positive impact on society and the environment.
About Farallon
Farallon Capital is a global investment management firm with over $40 billion in assets under management on behalf of a wide range of institutions, including university endowments, charitable foundations, and pension funds. Founded in 1986 and based in San Francisco, Farallon is an experienced institutional investment management firm investing across a variety of asset classes and jurisdictions. It aims to generate attractive risk-adjusted returns for its investors through rigorous fundamental analysis, a bottom-up approach and a focus on capital preservation.
About emeis
With nearly 83,500 experts and professionals in healthcare, nursing and support for the most vulnerable, emeis is present in some 20 countries and covers five business lines: psychiatric clinics, medical and rehabilitation clinics, nursing homes, home care and services, and assisted living facilities. emeis welcomes nearly 280,000 residents, patients, and beneficiaries each year. emeis is committed to addressing one of the major challenges facing our societies: the increase in the number of people made vulnerable by accidents, old age, or mental illness. emeis, which is 50.3% owned by Caisse des Dépôts, CNP Assurances, MAIF and MACSF Epargne Retraite, is listed on Euronext Paris (ISIN: FR001400NLM4) and is a member of the SBF 120 and CAC Mid 60 indices.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260114262830/en/
Contacts
Press Contact
TwentyTwo Real Estate
https://twentytwo.com/ -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwentytwo.com%
2F&esheet=54396617&newsitemid=20260114262830&lan=en-US&anchor=https%3A%2F%2Ftwen
tytwo.com%2F&index=2&md5=1e7b78ddba62c63626ee4628697cbf80
Dina Sanches – Communication Manager
M + 33 (0) 6 63 04 22 78 │dsanches@twentytwo.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom